Induction of Epstein-Barr virus antigens by hydroxyurea.
Treatment of the Epstein-Barr virus (EBV)-transformed, virus-producer P3HR-1 cell line with hydroxyurea (HU) resulted in increased synthesis of the EBV-specific early antigen (EA) and viral capsid antigen (VCA). The induction was noted already at a 200 mumol/l and reached plateau at a 1500 mumol/l HU concentration. At plateau concentration, the percentage of cells expressing EA and VCA was about 5 times higher than in the absence of the drug.